| ★ |  How to find hidden Antiphospholipid Syndrome (APS) | | 471 | — | |
| 9 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 74 |
| 1 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 81 |
| 8 |  Steroids in Relapsing Polychondritis | | 474 | — | 74 |
| 18 |  CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 71 |
| 10 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 73 |
| 6 |  Why morning joint stiffness and swelling in rheumatic diseases? | | 398 | — | 76 |
| 5 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 76 |
| 14 |  How to explain the antiphospholipid profile to my patients? | | 300 | — | 72 |
| 16 |  2026 focus on monogenic Ehlers-Danlos syndromes: periodontal and vascular variants | | 267 | — | 72 |
| 19 |  Systemic sclerosis and pregnancy, a 2026 update | | 257 | — | 70 |
| 12 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 73 |
| 7 |  Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 76 |
| 4 |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 76 |
| 17 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 71 |
| 15 |  Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 72 |
| 3 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 77 |
| 13 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 72 |
| 11 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 73 |
| 2 |  “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 79 |
| 20 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 70 |